The global exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is experiencing steady growth, driven by the rising prevalence of conditions such as chronic pancreatitis, cystic fibrosis, pancreatic cancer, and diabetes, which contribute to EPI. Increasing awareness about EPI symptoms and the importance of early diagnosis has led to higher demand for diagnostic tools like fecal elastase tests and imaging techniques. Therapeutic advancements, particularly in pancreatic enzyme replacement therapy (PERT), are improving patient outcomes and quality of life. The market is further supported by the development of novel drug formulations and a growing focus on personalized medicine. Ongoing research, supportive healthcare policies, and technological innovations in diagnostics and therapeutics are expected to drive the EPI market forward in the coming years.
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market is expected to reach USD 13.38 billion by 2030 from USD 7.67 bullion in 2022, growing CAGR of 7.2% during the forecast period 2023 to 2030.
To know more, visit https://www.databridgemarketresearch.com/reports/global-exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-market
Below are the Top Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Abbvie Inc.
|
AbbVie Inc. is a prominent player in the EPI therapeutics market, known for its development of innovative treatments targeting gastrointestinal disorders, including Exocrine Pancreatic Insufficiency. The company’s flagship product, Creon (pancrelipase), is a leading pancreatic enzyme replacement therapy (PERT) widely used in managing EPI. AbbVie focuses on research and development to improve enzyme formulations and enhance patient outcomes, solidifying its position as a key contributor to the global EPI therapeutics market.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In October 2022, AbbVie presented data at the American College of Gastroenterology Annual Scientific Meeting, highlighting the impact of CREON® (pancrelipase) on patient-reported daily symptoms in individuals with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery. This analysis underscores AbbVie's commitment to improving therapeutic outcomes and patient quality of life in the EPI therapeutics and diagnostics market.
|
|
2.
|
ABBOTT
|
Abbott is a global healthcare company that plays a vital role in the diagnostics segment of the EPI market. The company offers a wide range of diagnostic tools, including advanced laboratory tests and imaging technologies, that aid in the early detection and management of Exocrine Pancreatic Insufficiency. Abbott's commitment to innovation and precision in diagnostics ensures accurate and timely identification of EPI, contributing to better patient care and disease management.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In November 2022, Abbott announced that it had been awarded by the Consumer Technology Association (CTA) with three CES 2023 Innovation Awards for its life-changing technologies that are advancing the health tech industry and improving the lives of people worldwide.
|
|
3.
|
NESTLE
|
Nestlé Health Science is an influential player in the nutritional management of EPI, offering specialized medical nutrition products designed to support patients with digestive disorders. The company provides enzyme supplements and tailored dietary solutions that complement traditional EPI therapies, enhancing nutrient absorption and improving patients' quality of life. Nestlé's focus on medical nutrition as part of a holistic approach to managing EPI positions it as a key contributor to the market.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In February 2023, Codexis, Inc. and Nestlé Health Science announced the interim findings from a Phase 1 trial examining the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of CDX-7108. A lipase variation called CDX-7108 was created expressly to get around the drawbacks of the current pancreatic enzyme replacement treatment (PERT). This has aided the business in marketing the product.
|
|
4.
|
Laboratory Corporation of America Holdings
|
LabCorp is a leading provider of comprehensive diagnostic solutions, playing a significant role in the EPI diagnostics market. The company offers advanced laboratory testing services, including fecal elastase tests and genetic screening, which are critical for diagnosing Exocrine Pancreatic Insufficiency. LabCorp’s extensive network of diagnostic laboratories and commitment to accuracy and innovation make it a vital player in the early detection and management of EPI.
|
|
North America, Latin America, Middle East and Africa, Asia-Pacific, and Europe
|
In August 2022, Labcorp announced that it had closed its acquisition of RWJBarnabas Health’s outreach laboratory business and select related assets. RWJBarnabas Health is New Jersey’s largest academic health system. The acquisition will help in the growth of the business.
|
|
5.
|
JANSSEN GLOBAL SERVICES, LLC
|
Janssen Global Services, a pharmaceutical division of Johnson & Johnson, is actively involved in the development of gastrointestinal therapies, including those targeting EPI-related conditions. The company focuses on research and innovation in digestive health, contributing to advancements in the treatment of pancreatic insufficiency and related disorders. Janssen’s global presence and dedication to addressing unmet medical needs make it a significant player in the EPI therapeutics market.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In November 2023, Janssen Global Services, LLC, a subsidiary of Johnson & Johnson, discontinued the production of Pancreas HL, a pancreatic enzyme replacement therapy (PERT) used in the treatment of exocrine pancreatic insufficiency (EPI). This decision was made for commercial reasons and has contributed to the ongoing global shortage of PERT medications, impacting patients who rely on these therapies for effective digestion and nutrient absorption.
|
Conclusion
Global exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is set for continued growth, driven by the increasing incidence of pancreatic disorders and advancements in diagnostic and therapeutic solutions. The growing adoption of pancreatic enzyme replacement therapies (PERT) and improved diagnostic techniques are enhancing patient outcomes and facilitating early detection of EPI. While challenges such as high treatment costs and limited awareness in certain regions persist, ongoing research, technological innovation, and supportive healthcare policies are addressing these barriers. With a rising focus on personalized medicine and better healthcare infrastructure, the EPI market is poised to expand significantly in the coming years.
